{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"LexicalVariant","name":"CMA 676"},{"type":"CodeName","name":"CMA-676"},{"type":"USBrandName","name":"Mylotarg"},{"type":"CodeName","name":"CDP-771"},{"type":"Synonym","name":"Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody"},{"type":"CodeName","name":"WAY-CMA-676"},{"type":"Synonym","name":"hP67.6-Calicheamicin"},{"type":"NSCNumber","name":"720568"}],"definition":{"html":"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis.","text":"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/gemtuzumabozogamicin","text":"Gemtuzumab Ozogamicin"},"nciConceptId":"C1806","nciConceptName":"Gemtuzumab Ozogamicin","termId":42868,"name":"gemtuzumab ozogamicin","firstLetter":"g","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"gemtuzumab-ozogamicin"}],"links":null}